NCT04987112

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN1012 in Subjects With Unresectable or Metastatic Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: CanWell Pharma Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate CAN1012(Selective TLR7 agonist) when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.

Detailed description

This is a Phase 1, open-label, first-in-human, single-arm, multicenter, dose escalation study of IT CAN1012 in subjects with advanced solid tumors who are not candidates for standard therapy. Subjects will be enrolled in cohorts of 3 at each dose level using a 3+3 dose escalation design Approach.

Conditions

• Solid Tumor
• Cancer Metastatic

Interventions

Type	Name	Description
DRUG	CAN1012	CAN1012 IT injection (once every 4 weeks)

Timeline

• Start date: 2022-01-20
• Primary completion: 2024-12-30
• Completion: 2024-12-30
• First posted: 2021-08-03
• Last updated: 2023-12-22

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study